JP2018502834A5 - - Google Patents

Info

Publication number

JP2018502834A5

JP2018502834A5 JP2017529743A JP2017529743A JP2018502834A5 JP 2018502834 A5 JP2018502834 A5 JP 2018502834A5 JP 2017529743 A JP2017529743 A JP 2017529743A JP 2017529743 A JP2017529743 A JP 2017529743A JP 2018502834 A5 JP2018502834 A5 JP 2018502834A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

composition according

seq

antibody

aml

Prior art date

2015-12-02

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 38
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 35
• 230000005945 translocation Effects 0.000 claims description 20
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 15
• 239000003814 drug Substances 0.000 claims description 14
• 230000035772 mutation Effects 0.000 claims description 14
• 229940124597 therapeutic agent Drugs 0.000 claims description 13
• 210000000349 chromosome Anatomy 0.000 claims description 12
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 10
• 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 claims description 10
• 101710141832 DNA (cytosine-5)-methyltransferase 3 Proteins 0.000 claims description 10
• 102000012011 Isocitrate Dehydrogenase Human genes 0.000 claims description 10
• 108010075869 Isocitrate Dehydrogenase Proteins 0.000 claims description 10
• 230000001154 acute effect Effects 0.000 claims description 10
• 238000012423 maintenance Methods 0.000 claims description 10
• 230000005856 abnormality Effects 0.000 claims description 9
• 230000002068 genetic effect Effects 0.000 claims description 9
• 208000032839 leukemia Diseases 0.000 claims description 8
• 210000001726 chromosome structure Anatomy 0.000 claims description 7
• 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims description 7
• XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims description 6
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 6
• 229960003603 decitabine Drugs 0.000 claims description 6
• 229930002330 retinoic acid Natural products 0.000 claims description 6
• 238000002560 therapeutic procedure Methods 0.000 claims description 6
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 6
• 229960001727 tretinoin Drugs 0.000 claims description 6
• 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 claims description 5
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 5
• 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims description 5
• 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 claims description 5
• 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims description 5
• 210000004027 cell Anatomy 0.000 claims description 5
• 239000003623 enhancer Substances 0.000 claims description 5
• 102000052645 human CD38 Human genes 0.000 claims description 5
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 4
• 102100022678 Nucleophosmin Human genes 0.000 claims description 4
• 108010025568 Nucleophosmin Proteins 0.000 claims description 4
• 210000004369 blood Anatomy 0.000 claims description 4
• 239000008280 blood Substances 0.000 claims description 4
• 230000002759 chromosomal effect Effects 0.000 claims description 4
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 3
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 3
• 206010000871 Acute monocytic leukaemia Diseases 0.000 claims description 3
• 208000033496 Acute myeloid leukaemia with myelodysplasia-related features Diseases 0.000 claims description 3
• 206010008583 Chloroma Diseases 0.000 claims description 3
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 3
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 3
• 206010016654 Fibrosis Diseases 0.000 claims description 3
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 3
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
• 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims description 3
• 208000016544 acute myeloid leukemia with multilineage dysplasia Diseases 0.000 claims description 3
• 229960002756 azacitidine Drugs 0.000 claims description 3
• 210000001185 bone marrow Anatomy 0.000 claims description 3
• 229960002436 cladribine Drugs 0.000 claims description 3
• 239000003246 corticosteroid Substances 0.000 claims description 3
• 229960000684 cytarabine Drugs 0.000 claims description 3
• 229960000975 daunorubicin Drugs 0.000 claims description 3
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 3
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
• 229960003957 dexamethasone Drugs 0.000 claims description 3
• 229960004679 doxorubicin Drugs 0.000 claims description 3
• 230000004761 fibrosis Effects 0.000 claims description 3
• 238000009093 first-line therapy Methods 0.000 claims description 3
• -1 fludarabin Chemical compound 0.000 claims description 3
• 229960000908 idarubicin Drugs 0.000 claims description 3
• 238000009115 maintenance therapy Methods 0.000 claims description 3
• 229960000485 methotrexate Drugs 0.000 claims description 3
• 229960001156 mitoxantrone Drugs 0.000 claims description 3
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 3
• 201000005987 myeloid sarcoma Diseases 0.000 claims description 3
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
• 238000001959 radiotherapy Methods 0.000 claims description 3
• 230000000306 recurrent effect Effects 0.000 claims description 3
• 229960003087 tioguanine Drugs 0.000 claims description 3
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 3
• 229960000303 topotecan Drugs 0.000 claims description 3
• HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims description 2
• 108091032955 Bacterial small RNA Proteins 0.000 claims description 2
• 206010050026 Panmyelopathy Diseases 0.000 claims description 2
• 230000000735 allogeneic effect Effects 0.000 claims description 2
• 210000004381 amniotic fluid Anatomy 0.000 claims description 2
• 230000001640 apoptogenic effect Effects 0.000 claims description 2
• GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims description 2
• 229960001334 corticosteroids Drugs 0.000 claims description 2
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
• 229960005420 etoposide Drugs 0.000 claims description 2
• 210000000130 stem cell Anatomy 0.000 claims description 2
• 230000001629 suppression Effects 0.000 claims description 2
• 238000002054 transplantation Methods 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 26
• 125000003275 alpha amino acid group Chemical group 0.000 claims 4
• 239000003937 drug carrier Substances 0.000 claims 2
• 208000036566 Erythroleukaemia Diseases 0.000 claims 1
• 101000708766 Homo sapiens Structural maintenance of chromosomes protein 3 Proteins 0.000 claims 1
• 108091000080 Phosphotransferase Proteins 0.000 claims 1
• 102100032723 Structural maintenance of chromosomes protein 3 Human genes 0.000 claims 1
• 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
• 239000012752 auxiliary agent Substances 0.000 claims 1
• 239000003085 diluting agent Substances 0.000 claims 1
• 239000000546 pharmaceutical excipient Substances 0.000 claims 1
• 102000020233 phosphotransferase Human genes 0.000 claims 1
• 239000003981 vehicle Substances 0.000 claims 1
• 238000000034 method Methods 0.000 description 26
• 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 8
• 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 8
• 150000001413 amino acids Chemical class 0.000 description 5
• 102100038501 Splicing factor U2AF 35 kDa subunit Human genes 0.000 description 4
• 101710094463 Splicing factor U2AF 35 kDa subunit Proteins 0.000 description 4
• 108010000597 Polycomb Repressive Complex 2 Proteins 0.000 description 2
• 102000002272 Polycomb Repressive Complex 2 Human genes 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• 206010069754 Acquired gene mutation Diseases 0.000 description 1
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
• 206010028980 Neoplasm Diseases 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 150000004676 glycans Chemical group 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 230000007918 pathogenicity Effects 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 108090000623 proteins and genes Proteins 0.000 description 1
• 230000037439 somatic mutation Effects 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1